At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.
Biogen contributes to the communities where we live. We are committed to our employees, diversity, equity and inclusion, and environmental sustainability.
We came to Biogen to solve the unsolvable. We stay to create new possibilities and grow together. We work fearlessly and go beyond because we care deeply about making a difference and changing lives. All legitimate correspondence from a Biogen employee will come from “@biogen.com” or “@smartrecruiters.com” email accounts.
Our world-class neurology research and development organization is pushing towards novel approaches for previously intractable neurodegenerative conditions such as Alzheimer’s disease.
Today there are no treatments to prevent, delay or stop the disease progression.
Alzheimer’s disease is a progressive neurological illness that impairs thinking and independence of millions of people worldwide.1 Today, more than 5 million Americans and more than 40 million people worldwide are living with Alzheimer’s disease and related dementias, and these numbers are growing rapidly.
This disease destroys not only quality of life but also quantity – it is the 3rd leading cause of mortality in people over 65, behind cancer and heart disease.
Alzheimer’s disease is usually diagnosed in people 65 and older, but it starts earlier with subtle neurological changes occurring years or even decades before symptoms appear. Many people are experiencing the early, often unrecognized, signs of mild cognitive impairment.
5+ million Americans & 40+ million people globally live with #Alzheimer’s disease & other dementias
Driven by our commitment to patients and our strong business foundation, Biogen remains committed to furthering Alzheimer’s disease research and treatment, aiming to help address the unmet needs in this devastating condition, with an emphasis on early-stage disease.
Below you’ll find our current investigational therapies in Alzheimer’s disease.
Investigational candidates in Alzheimer's disease
Filter By
All
All
Alzheimer's Disease
All
All
Filed
Phase 3
Phase 2
Phase 1
P1Phase 1
P2Phase 2
P3Phase 3
Filed
Aducanumab (Aβ mAb)
Alzheimer’s disease
Developed in collaboration with Eisai Co., Ltd.
Licensed from Neurimmune.
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.
Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.
How this investigational therapy could help:
The memory loss and functional decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in the brain. Aducanumab is an antibody that binds to and may reduce amyloid plaques from the brain, potentially slowing the progress of the disease.
Learn more about EMERGE and ENGAGE, clinical trials for Alzheimer’s disease.
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.
Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.
How this investigational therapy could help:
The memory loss and functionality decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in the brain. BAN2401 is an antibody that binds to amyloid, which could reduce its presence in the brain and potentially slow the progress of the disease.
1 World Health Organization Dementia a Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed 23 May 2016.
BIIB092 (gosuranemab)
Alzheimer's disease
Licensed from Bristol-Myers Squibb.
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.
Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.
How this investigational therapy could help:
The memory loss and functional decline of AD have been linked to abnormal protein deposits that build up in the brain. Among those proteins are amyloid and tau. Deposits of abnormal tau, so-called neurofibrillary tangles, form in the neurons and are linked to increasing impairment and loss of brain cells associated both with AD and with other neurodegenerative diseases, known as tauopathies, such as progressive supranuclear palsy and frontotemporal dementia. BIIB092 (gosuranemab) is an antibody targeting extracellular tau and may reduce the spreading of tau from one cell to the next, potentially slowing the progress of the disease.
1 World Health Organization Dementia a Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed 23 May 2016.
BIIB076 (anti-tau mAb)
Alzheimer's disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.
Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.
How this investigational therapy could help:
The memory loss and functional decline of AD have been linked to abnormal protein deposits that build up in the brain. Among those proteins are amyloid and tau. Deposits of abnormal tau, so-called neurofibrillary tangles, form in the neurons and are linked to increasing impairment and loss of brain cells associated both with AD and with other neurodegenerative diseases, known as tauopathies, such as progressive supranuclear palsy and frontotemporal dementia. BIIB076 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain.
1 World Health Organization Dementia a Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed 23 May 2016.
BIIB080 (IONIS-MAPTRx)
Alzheimer's disease
Developed in collaboration with Ionis Pharmaceuticals.
*Option to acquire from Ionis Pharmaceuticals.
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1. Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.
How this investigational therapy could help:
The memory loss and functional decline of Alzheimer’s disease have been linked to amyloid plaques and tau tangles, abnormal protein deposits that build up in the brain and in the brain cells. BIIB080 (IONIS-MAPTRx) is an antisense oligonucleotide (ASO) that may reduce production of the tau protein and its accumulation in brain cells, potentially slowing the progress of the disease.
In partnership with the medical community and patient advocacy groups, Biogen encourages clinical trial enrollment for people in the early stages of Alzheimer’s disease.
Biogen conducts clinical trials to evaluate the efficacy and safety of investigational therapies in our pipeline, including Alzheimer’s disease.
Deciding to participate in a clinical trial requires careful consideration. In most cases, the therapies investigated in clinical trials are not yet approved by regulatory agencies like the Food and Drug Administration (FDA) in the United States. The benefits and risks of taking the treatment are not completely known. By volunteering for a clinical trial, you are helping the medical community determine whether new treatments are safe and effective.
You are now leaving Biogen’s corporate website.
We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from Biogen’s standards.
Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.
